milan : REC

November 29, 2011 04:25 ET


MILAN, ITALY--(Marketwire - Nov 29, 2011) - Pursuant to Article 2.6.2, paragraph 1, letter c) of Borsa Italiana S.p.A.'s Regulation, Recordati S.p.A. hereby communicates the calendar of corporate events for 2012.

9(th) February Board of Directors' meeting to approve the 2011 preliminary consolidated results.

8(th) March Board of Directors' meeting to approve the 2011 consolidated financial statements and the draft of Recordati S.p.A.'s 2011 financial statements.

19(th) April Shareholders' General Meeting to approve the 2011 Financial Statements.

8(th) May Board of Directors' meeting to approve the 2012 first quarter interim management statement.

9(th) May Presentation to financial analysts.

26(th) July Board of Directors' meeting to approve the 2012 half-yearly report.

25(th) October Board of Directors' meeting to approve the 2012 first nine months' interim management statement.

Recordati, established in 1926, is a European pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271),with a total staff of over 2,800, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. It has headquarters in Milan, Italy, operations in the main European countries, and a growing presence in the new markets of Central and Eastern Europe. A European field force of around 1,400 medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati's current and growing coverage of the European pharmaceutical market makes it a partner of choice for new product licenses from companies which do not have European marketing organizations. Recordati is committed to the research and development of new drug entities within the cardiovascular and urogenital therapeutic areas and of treatments for rare diseases. Consolidated revenue for 2010 was EUR 728.1 million, operating income was EUR 154.8 million and net income was EUR 108.6 million.


This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.


Contact Information